Author

Miguel Regueiro 1

1 Cleveland Clinic Main Campus

Best of IBD

Miguel Regueiro

EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY

Remo Panaccione, Anita Afzali, David P. Hudesman, Garrett Lawlor, Mark T. Osterman, Arteid Memaj, Miguel Regueiro, Subrata Ghosh

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Miguel Regueiro

MIRIKIZUMAB THERAPY IS ASSOCIATED WITH IMPROVED FATIGUE IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Miguel Regueiro, Mingyang Shan, Paul Pollack, Lai Shan Chan, Pieter Hindryckx, Theresa Hunter Gibble, Monika Fischer, David T. Rubin, Deanilee Deckard

NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY

Geert R. D'Haens, Genoile O. Santana, William J. Sandborn, Irene Modesto, Chinyu Su, Nervin Lawendy, Jerome Paulissen, Marla C. Dubinsky, Miguel Regueiro, nicole kulisek, Sean Gardiner, Rajiv Mundayat, Joana Torres

Predictors of delayed response to tofacitinib: results of the octave open study for delayed responders

Miguel Regueiro, Jami A. Kinnucan, Ryan Ungaro, Daniel Quirk, Chinyu Su, Nervin Lawendy, Haiyun Fan, Deborah.A Woodworth, Markus F. Neurath

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Hongjuan Liu, AnnKatrin Petersen, Jean-Frédéric Colombel, Lorna Charles, Michael Silver, James K. Sheffield, Neil Minton, Marc Gleichmann, Jon Riolo, Diego Silva, Bruce A. C. Cree, Robert T. Naismith, Miguel Regueiro

Item 1 - 7 / 9
1